AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32701874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 32106832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6.
Number of subjects: 30
Study 32106832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32106832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 30
Study 35137448 — intervention group
Group type: COMPARATOR
Intervention: TM only group
Number of subjects: 6
Study 35137448 — intervention group
Group type: EXPERIMENTAL
Intervention: TM+BS group
Number of subjects: 6
Study 35137448 — intervention group
Group type: EXPERIMENTAL
Intervention: TM+CM group
Number of subjects: 6
Study 35137448 — intervention group
Group type: EXPERIMENTAL
Intervention: TM+BS+CM group
Number of subjects: 6
Study 34237976 — intervention group
Group type: EXPERIMENTAL
Intervention: Family enteral nutrition (FEN)
Number of subjects: 106
Study 34237976 — intervention group
Group type: COMPARATOR
Intervention: Regular meals (control)
Number of subjects: 106
Study 32155594 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot-reduced IMPT plan
Number of subjects: 1
Study 32155594 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical plan
Number of subjects: 1
Study 32819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability measurement of HVI angle
Number of subjects: 16
Study 32819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability measurement of HVI angle
Number of subjects: 16
Study 32819157 — intervention group
Group type: COMPARATOR
Intervention: Surgeons' level of experience
Number of subjects: 16
Study 32417634 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 μg/day) and coenzyme Q10 (200 mg/day)
Number of subjects: 219
Study 32417634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 32995961 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric quasi-isometric (EQI) contractions
Number of subjects: 15
Study 32995961 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic eccentric (ECC) contractions
Number of subjects: 15
Study 33038664 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 22
Study 34753667 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention (weekly supervised circuit exercise 30 min/week, health education session 10 min/week, lunchtime sports activities 20 min/week)
Number of subjects: 160
Study 34753667 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention
Number of subjects: 160
Study 33179822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D magnetic resonance fingerprinting with quadratic RF phase (qRF‐MRF)
Number of subjects: 0
Study 32563378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g loading dose followed by 3 g maintenance dose over 24 hours)
Number of subjects: 12009
Study 32563378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 12009
Study 32563378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 12009
Study 32563378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12009
Study 35147195 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (300 µg, 1.8 ml)
Number of subjects: 245
Study 35147195 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1.8 ml)
Number of subjects: 245
Study 34732440 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESP Block)
Number of subjects: 104
Study 34732440 — intervention group
Group type: COMPARATOR
Intervention: Serratus plane block (SPB) plus pectoral nerve blocks (PECS I)
Number of subjects: 104
Study 32921096 — intervention group
Group type: EXPERIMENTAL
Intervention: HX110-A
Number of subjects: 0
Study 32921096 — intervention group
Group type: EXPERIMENTAL
Intervention: HX110-B
Number of subjects: 0
Study 32921096 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35945818 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB-only group (n = 36)
Number of subjects: 85
Study 35945818 — intervention group
Group type: COMPARATOR
Intervention: DES group (n = 49)
Number of subjects: 85
Study 32719354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72
Study 32719354 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RES)
Number of subjects: 72
Study 32719354 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 72
Study 1997163897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2000000 IU as a bolus + 500000 JU/h until the end of the operation)
Number of subjects: 18
Study 1997163897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 36437523 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 152
Study 36437523 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of whole grain cereals, fruits, vegetables, and fish; lower intake of sweets
Number of subjects: 152
Study 33512413 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 401
Study 32681911 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced WTR astigmatism (1-D increase)
Number of subjects: 15
Study 34294550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU weekly for 12 weeks)
Number of subjects: 86
Study 34294550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 34269257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion of 1 mg/kg/h
Number of subjects: 64
Study 34269257 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion of 1.5-6 mg/kg/h
Number of subjects: 64
Study 32101145 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative forced-air and intravenous fluid warming
Number of subjects: 135
Study 32101145 — intervention group
Group type: COMPARATOR
Intervention: No active warming
Number of subjects: 135
Study 35883082 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone‐7 (90 µg/day)
Number of subjects: 84
Study 32769826 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 123
Study 32769826 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 123
Study 32075666 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 kHz stimulation
Number of subjects: 14
Study 36196478 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP-medication group (second-generation antipsychotic medication)
Number of subjects: 81
Study 36196478 — intervention group
Group type: COMPARATOR
Intervention: FEP-placebo group
Number of subjects: 81
Study 36196478 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 81
Study 36196478 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP-medication group
Number of subjects: 81
Study 34807661 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster within-treatment improvement of PTSD symptoms
Number of subjects: 70
Study 34807661 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time employment
Number of subjects: 70
Study 34807661 — intervention group
Group type: COMPARATOR
Intervention: Age and speed of PTSD improvement interaction
Number of subjects: 70
Study 36242831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU), twice daily for three days
Number of subjects: 39
Study 36242831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 32610330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Therapy (CT)
Number of subjects: 76
Study 32610330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 34461950 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate FET (first menstrual cycle after failed IVF-ET)
Number of subjects: 732
Study 34461950 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate FET
Number of subjects: 732
Study 32832550 — intervention group
Group type: EXPERIMENTAL
Intervention: TACIA score (new prognostic model)
Number of subjects: 308
Study 34967801 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise training
Number of subjects: 50
Study 34967801 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous plus HIIT
Number of subjects: 50
Study 34967801 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous plus BFR training combined with HIIT (BFRIT)
Number of subjects: 50
Study 33397767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihormonal artificial pancreas (AP) therapy, 2-week duration
Number of subjects: 23
Study 33397767 — intervention group
Group type: COMPARATOR
Intervention: Open loop control (patient's normal insulin pump therapy), 2-week duration
Number of subjects: 23
Study 33368617 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diazepam
Number of subjects: 30
Study 33368617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32044942 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (n=785)
Number of subjects: 1548
Study 32044942 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing (n=763)
Number of subjects: 1548
Study 33522891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (1.25 g·kg body mass‐1 at -1°C) during HA training
Number of subjects: 7
Study 33522891 — intervention group
Group type: COMPARATOR
Intervention: Room temperature beverage ingestion (NOC: 36.5°C) during HA training
Number of subjects: 7
Study 34633434 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain interventions targeting vascular risk factors
Number of subjects: 0
Study 34633434 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33310053 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 155
Study 33310053 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 155
Study 33310053 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 155
Study 35964000 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week mindfulness program
Number of subjects: 150
Study 35964000 — intervention group
Group type: COMPARATOR
Intervention: Eight-week, placebo-controlled lifestyle education program
Number of subjects: 150
Study 35964000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Number of subjects: 150
Study 34167523 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) intervention conducted in eight 90-min sessions
Number of subjects: 63
Study 34167523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 32817701 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Care (SC)
Number of subjects: 700
Study 32817701 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 700
Study 36039657 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2017-HCF
Number of subjects: 330
Study 36039657 — intervention group
Group type: COMPARATOR
Intervention: GP2017
Number of subjects: 330
Study 33905343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 6-min simple resistance activities (SRA6) every 60 min
Number of subjects: 23
Study 33905343 — intervention group
Group type: COMPARATOR
Intervention: Sitting with 3-min simple resistance activities (SRA3) every 30 min
Number of subjects: 23
Study 33905343 — intervention group
Group type: COMPARATOR
Intervention: Sitting uninterrupted for 7 hours (SIT)
Number of subjects: 23
Study 36198994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg) with 30 placebo capsules of probiotic
Number of subjects: 80
Study 36198994 — intervention group
Group type: COMPARATOR
Intervention: Probiotic (30 capsules containing 1 × 10^9 CFU/g LA‐5) with 1 fluconazole placebo capsule
Number of subjects: 80
Study 36198994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 80
Study 36198994 — intervention group
Group type: COMPARATOR
Intervention: Probiotic
Number of subjects: 80
Study 36198994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole and Probiotic
Number of subjects: 80
Study 32701225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin infusion during robot-assisted retinal vein cannulation
Number of subjects: 4
Study 32701225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin infusion
Number of subjects: 4
Study 32865145 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB (MDT-2113, IN.PACT Admiral)
Number of subjects: 100
Study 32865145 — intervention group
Group type: COMPARATOR
Intervention: PTA (Percutaneous Transluminal Angioplasty)
Number of subjects: 100
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY-19489 1500 mg
Number of subjects: 71
Study 35247321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY-19489 (300 mg) in fed state
Number of subjects: 71
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY-19489 (300 mg) in fasted state
Number of subjects: 71
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY-19489 (200 mg)
Number of subjects: 71
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY-19489 (300 mg)
Number of subjects: 71
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: ZY-19489 (900 mg)
Number of subjects: 71
Study 35247321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic-Pharmacodynamic model simulation for 1100 mg
Number of subjects: 71
Study 32962980 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50MET-low
Number of subjects: 484
Study 32962980 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50MET-high
Number of subjects: 484
Study 32962980 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50MET-low (BOLERO-2)
Number of subjects: 484
Study 32962980 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50MET-high (BOLERO-2)
Number of subjects: 484
Study 33301819 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (n = 58)
Number of subjects: 107
Study 32005622 — intervention group
Group type: EXPERIMENTAL
Intervention: IPACK block
Number of subjects: 69
Study 35450456 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30% sodium hyaluronate ocular gel
Number of subjects: 70
Study 35450456 — intervention group
Group type: COMPARATOR
Intervention: 0.18% sodium hyaluronate eye drops
Number of subjects: 70
Study 33561455 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 2325
Study 33561455 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients (BMI < 30 kg/m2)
Number of subjects: 2325
Study 35749525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1743
Study 35749525 — intervention group
Group type: COMPARATOR
Intervention: No postmastectomy radiotherapy (no-PMRT)
Number of subjects: 1743
Study 35749525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) in patients with three nodes positive
Number of subjects: 1743
Study 35749525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) in patients with one or two nodes positive
Number of subjects: 1743
Study 35749525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT) in TNBC patients with T2 tumor and three positive lymph nodes
Number of subjects: 1743
Study 32962443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 0
Study 32962443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35612589 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 184
Study 35612589 — intervention group
Group type: EXPERIMENTAL
Intervention: Amerindian ethnicity
Number of subjects: 184
Study 35612589 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (head and neck-limited)
Number of subjects: 184
Study 35612589 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical and serological features
Number of subjects: 184
Study 35445520 — intervention group
Group type: EXPERIMENTAL
Intervention: SlowMo therapy
Number of subjects: 22
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp model for screening hepatobiliary diseases
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus model for screening hepatobiliary diseases
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp model for identifying liver cancer
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus model for identifying liver cancer
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp model for identifying liver cirrhosis
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus model for identifying liver cirrhosis
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp model for identifying other hepatobiliary diseases
Number of subjects: 1252
Study 33509389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus model for identifying other hepatobiliary diseases
Number of subjects: 1252
Study 32541398 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based, ROM-assisted group psychotherapy
Number of subjects: 25
Study 32541398 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 25
Study 35780790 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of bandage group
Number of subjects: 965
Study 35780790 — intervention group
Group type: COMPARATOR
Intervention: Rigid immobilisation group
Number of subjects: 965
Study 34637332 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 6564
Study 34637332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6564
Study 34648352 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX‐HAIC (oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2,400 mg/m2 for 24 hours, once every 3 weeks)
Number of subjects: 315
Study 34648352 — intervention group
Group type: COMPARATOR
Intervention: TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles)
Number of subjects: 315
Study 34336000 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-Learning Genomics (DLG) model
Number of subjects: 1461
Study 34336000 — intervention group
Group type: COMPARATOR
Intervention: Traditional GWAS analysis
Number of subjects: 1461
Study 33201116 — intervention group
Group type: EXPERIMENTAL
Intervention: sNPWT dressing
Number of subjects: 146
Study 33201116 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 146
Study 32746835 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR)
Number of subjects: 9143
Study 32746835 — intervention group
Group type: COMPARATOR
Intervention: No primary tumor resection (non-PTR)
Number of subjects: 9143
Study 34246153 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality app (six 30‐min sessions at home over a two‐week period)
Number of subjects: 66
Study 34246153 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 66
Study 35797108 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 13
Study 35797108 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 13
Study 32134128 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative simple transfusion
Number of subjects: 138
Study 32134128 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 138
Study 35237342 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin combined with vitamin E
Number of subjects: 134
Study 35237342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 134
Study 34701332 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 maintenance therapy
Number of subjects: 183
Study 34701332 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 183
Study 33228899 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise-canceling headphones (NCHs) with music
Number of subjects: 490
Study 33228899 — intervention group
Group type: COMPARATOR
Intervention: Non-NCH hearing protection alone
Number of subjects: 490
Study 34856826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (standardized protocol, twice per week for 5 weeks)
Number of subjects: 24
Study 34856826 — intervention group
Group type: COMPARATOR
Intervention: Attention control protocol
Number of subjects: 24
Study 34678887 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block with 75 mg of bupivacaine plus 50 μg of fentanyl
Number of subjects: 60
Study 34678887 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 15 mg of bupivacaine and 50 μg fentanyl
Number of subjects: 60
Study 34678887 — intervention group
Group type: EXPERIMENTAL
Intervention: Saddle block with 15 mg of bupivacaine and 50 μg of fentanyl
Number of subjects: 60
Study 32808455 — intervention group
Group type: COMPARATOR
Intervention: Person-centred care interventions
Number of subjects: 27
Study 36448475 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard self-monitoring with no microinterventions
Number of subjects: 264
Study 36448475 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills monitoring with no microinterventions
Number of subjects: 264
Study 36448475 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard self-monitoring with automated microinterventions
Number of subjects: 264
Study 36448475 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills monitoring with automated microinterventions
Number of subjects: 264
Study 36448475 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard self-monitoring with just-in-time adaptive interventions
Number of subjects: 264